New research reveals striking similarities between ancient and modern oceanic crust, shedding light on early Earth's heat loss and tectonic settings. The study extends the record of oceanic crust generation back to at least 3.8 billion years ago.
A new study presents exciting data showing that quadruple therapy can achieve a 100% sustained virological response (SVR) rate in HCV patients who have failed previous treatments. This breakthrough could mark the next generation of HCV treatment and provide new hope for thousands of patients worldwide.
The American Association for Cancer Research is prioritizing clinical trials to advance cancer treatment and prevention. Researchers presented findings on basal cell cancer and lung cancer, highlighting the potential of biomarkers and hedgehog pathway inhibitors. New discoveries aim to improve patient outcomes and reduce side effects.
A study of twin veterans found that antidepressant use is linked to thicker arteries, contributing to the risk of heart disease and stroke. The data suggests that antidepressants may combine with depression for a negative effect on blood vessels.
A new hedgehog pathway inhibitor, GDC-0449, demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome. The drug reduced the development of new lesions and decreased tumor size, offering a promising treatment option for these patients.
Researchers testing a combination of GDC-0973 and GDC-0941, which inhibit the RAS/RAF/MEK and PI3K pathways, report encouraging safety data and early signs of anti-tumor activity. Patients with various types of cancer have shown decreases in tumor size, suggesting potential benefits for targeted therapy.
A new study found thalidomide significantly increased two-year disease-free survival rate (65%) compared to placebo (33%). However, overall survival rates were comparable between treatment groups. This finding provides new hope for difficult-to-treat liver cancer patients.
Researchers sequenced whole genomes of tumors from 50 breast cancer patients and compared them to healthy cells, finding over 1,700 unique mutations. The study identified three significant mutations that may be common in ER-positive breast cancers, offering new avenues for personalized treatment.
Researchers have successfully infected and replicated swine hepatitis E virus in human hepatocytes, confirming its zoonotic potential. This breakthrough verifies the infectious disease can be transmitted from animals to humans., Hepatitis E is a major cause of epidemic and acute sporadic hepatitis worldwide.
A genetic variant has been linked to both longer telomeres and a reduced risk of bladder cancer, according to researchers. The study found that the variant, rs398652, was associated with a 19% reduction in bladder cancer risk.
Researchers have identified a biomarker for measuring the success of lung cancer chemoprevention, using abnormal cell development (endobronchial dysplasia). The study found that measurements of endobronchial dysplasia can predict how well a chemoprevention agent is working in former smokers.
In a Phase IIb study of 526 treatment-naive hepatitis C patients, PEG-Interferon lambda achieved higher rates of rapid virologic response and complete early virologic response compared to PEG-Interferon alfa. The study also showed fewer flu-like symptoms and cytopenias in the PEG-Interferon lambda arms.
Researchers present promising entry inhibitors, a new mechanism of action for treating viral hepatitis B and D infections. These drugs could provide the first new treatments in many years and have shown high effectiveness against HBV infection, reducing markers by 90%.
Engineers at Harvard University have discovered that individual, vertical silicon nanowires can display vibrant colors of the spectrum, dependent on their diameter. The finding has potential applications in increasing efficiency and detecting color without filters in nanoscale image sensor devices.
Researchers at UT MD Anderson Cancer Center developed two sets of gene expression profiles that predict response to erlotinib treatment for patients with no guiding indicators. The biomarkers, which cover 88% of patients without EGFR mutations, may have a broad impact on identifying patients who benefit from the drug.
Researchers at the BATTLE trial have identified two novel gene markers, including an EMT signature and LCN2, that predict response to EGFR inhibition in patients with wild-type EGFR. These biomarkers may help identify patients who can benefit from erlotinib treatment.
A study found that improved quality of life and reduced stress response were associated with changes in telomere length in cancer patients. Psychological counseling had a potential impact on modulating telomere length, but the findings require further exploration.
New data show that NAFLD prevalence in the US is expected to increase by 50% by 2030, driven by rising obesity and diabetes rates. The condition can progress to advanced liver disease, significantly impacting mortality rates.
Researchers discovered a single genetic variation associated with a 19% decrease in bladder cancer risk and longer telomeres, which guard against chromosomal damage. The finding provides new clues for understanding the causes of bladder cancer and developing therapies to reduce cancer risk.
Researchers sequenced whole genomes of tumors from 50 breast cancer patients and compared them to healthy cells, finding over 1,700 unique mutations. The study highlights the complexity of cancer genomes and offers new insights into personalized medicine.
Researchers have synthesized a novel class of amphiphilic dendronized homopolymers with variable amphiphilicity, showing thermoresponsiveness and forming ordered porous films. These polymers adopt helical conformations in solution and can be used to develop new amphiphilic polymer structures.
Rapid resistance to novel antiviral therapy develops in response to direct antiviral drugs for hepatitis C virus (HCV) treatment. New HCV treatments face resistance concerns, experts advise careful prescription and monitoring to minimize rapid development. NS3-protease and NS5A inhibitors block essential enzymes for HCV replication.
Young people aged 10-15 report being happier with family situations when mothers are happy, but only 55% of unhappy mothers' kids are 'completely happy'. The happiest children live with two parents without younger siblings and have a positive relationship with their mother.
The study of the early Cambrian Guanshan biota provides new insights into its sedimentology, taphonomy, and biodiversity. The fossil groups recovered include lobopods, eldonids, hyolithids, green algae, and several others, with preserved soft-tissues rivaling those from the Chengjiang fauna.
A Phase II dose-ranging study of BMS-790052 plus PEG-interferon alfa and ribavirin showed higher rates of sustained virologic response compared to PEG-interferon alfa and ribavirin alone. The regimen achieved up to 92% SVR12 in treatment-naïve patients with hepatitis C genotype 1.
PegIFN-lambda demonstrates better rapid and complete virological responses than PegIFN-alpha-2a in HCV patients, with fewer side effects. The new therapy holds promise as a future standard of care for chronic HCV treatment.